About Caladrius

Caladrius Biosciences, Inc. is a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases.

News

July 15, 2019
Caladrius Biosciences Receives Advanced Therapy Medicinal Product Classification for CLBS12, its CD34+ Cell Therapy for Critical Limb Ischemia

June 4, 2019
Caladrius Biosciences Completes Enrollment in Phase 2 ESCaPE-CMD Trial for Coronary Microvascular Dysfunction

May 9, 2019
Caladrius Biosciences Reports 2019 First Quarter Financial Results and Provides Corporate Update

Events

May 9, 2019
Caladrius Biosciences 1st Quarter 2019 Financial Results and Business Update Conference Call

March 21, 2019
ARM’s Cell & Gene Therapy Investor Day

March 14, 2019
Caladrius Biosciences 4th Quarter 2018 Financial Results and Business Update Conference Call

Sign up to our e-mail list to receive Caladrius announcements.

Technologies & Capabilities

T Regulatory Cell Technology

T Regulatory Cell Technology

CD34 Cell Technology

CD34 Cell Technology